Your session is about to expire
← Back to Search
Rifaximin for Liver Damage
Study Summary
This trial is studying how a drug affects the body over time.
- Severe Liver Damage
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 222 Patients • NCT01842581Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What risk factors should be considered when administering Rifaximin to patients?
"The safety of rifaximin has been verified through extensive clinical trials and is therefore assigned a score of 3."
What is the aggregate quantity of participants signed up for this experiment?
"Affirmative. According to information found on clinicaltrials.gov, this medical trial was initially posted in December 2018 and is currently recruiting participants. The programme necessitates 18 patients from one specific site."
Is recruitment currently open for this clinical investigation?
"Affirmative. According to clinicaltrials.gov, recruitment is ongoing for this study which was established on December 5th 2018 and updated as recently as September 7th 2022. 18 individuals need to be enrolled at 1 site in order to complete the trial's requirements."
What conditions are typically addressed with Rifaximin treatments?
"Rifaximin is frequently prescribed to prevent relapses of clostridium difficile infection, but can also be used to treat Irritable Bowel Syndrome (IBS), bacterial infections, and diarrhea."
Share this study with friends
Copy Link
Messenger